The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•31 March 2026•

1 min read

Telomir Pharmaceuticals Files FDA IND Application for Breast Cancer Therapy

Key Facts

1Telomir Pharmaceuticals (NASDAQ: TELO) submitted an Investigational New Drug (IND) application to the FDA for its lead candidate, Telomir-1.

2The drug candidate targets advanced and metastatic Triple-Negative Breast Cancer (TNBC).

3Telomir-1 is a metal-modulating epigenetic therapy targeting iron-dependent pathways in cancer cells.

Create Free Account

Version History

1 additional source confirmed this story

Telomir Pharmaceuticals (NASDAQ: TELO) has officially submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for its lead candidate, Telomir-1. The therapeutic candidate is specifically designed to target advanced and metastatic Triple-Negative Breast Cancer (TNBC), a challenging form of the disease. Telomir-1 utilizes a metal-modulating epigenetic approach that targets iron-dependent pathways within cancer cells to inhibit their progression. This submission follows successful preclinical efficacy studies which demonstrated a favorable safety profile for the small-molecule drug. The filing marks a significant milestone for the company as it transitions from preclinical development to human clinical trials. Regulatory progress of this nature is typically viewed as a key value driver for biotech firms, potentially increasing investor interest in TELO.